Moneycontrol PRO
HomeNewsBusinessCompaniesCadila gets 5 observations from USFDA for subsidiary's injectables facility

Cadila gets 5 observations from USFDA for subsidiary's injectables facility

United States Food and Drug Administration (USFDA) conducted the inspection from August 20-28. Liva is a 100 percent subsidiary of Cadila Healthcare.

August 29, 2018 / 13:13 IST

Cadila Healthcare today said the US health regulator has issued five observations after inspection of its subsidiary Liva Pharmaceuticals' injectables manufacturing facility.

"This was a product specific pre-approval inspection. It concluded with 5 observations. Liva will respond to USFDA within 15 days. It may be noted that at present Liva does not export any products to the US market," Cadila Healthcare said in a filing to BSE. The injectables facility is located at Vadodara.

United States Food and Drug Administration (USFDA) conducted the inspection from August 20-28. Liva is a 100 percent subsidiary of Cadila Healthcare.

Shares of Cadila Healthcare were trading 1.78 percent lower at Rs 389.40 apiece on BSE.

PTI
first published: Aug 29, 2018 01:10 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347